Cardiovascular risk and testosterone - from subclinical atherosclerosis to lipoprotein function to heart failure

Rev Endocr Metab Disord. 2021 Feb 22. doi: 10.1007/s11154-021-09628-2. Online ahead of print.ABSTRACTThe cardiovascular (CV) benefit and safety of treating low testosterone conditions is a matter of debate. Although testosterone deficiency has been linked to a rise in major adverse CV events, most of the studies on testosterone replacement therapy were not designed to assess CV risk and thus excluded men with advanced heart failure or recent history of myocardial infarction or stroke. Besides considering observational, interventional and prospective studies, this review article evaluates the impact of testosterone on atherosclerosis process, including lipoprotein functionality, progression of carotid intima media thickness, inflammation, coagulation and thromboembolism, quantification of plaque volume and vascular calcification. Until adequately powered studies evaluating testosterone effects in hypogonadal men at increased CV risk are available (TRAVERSE trial), clinicians should ponder the use of testosterone in men with atherosclerotic cardiovascular disease and discuss benefit and harms with the patients.PMID:33616800 | DOI:10.1007/s11154-021-09628-2
Source: ENDOCR REV - Category: Endocrinology Authors: Source Type: research